Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1527 - Preliminary Results from a Phase 1 Study of GBR 1302, A Bispecific Antibody T-Cell Engager, in HER2 Positive Cancers


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Clinical Research

Tumour Site


Martin Wermke


Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288


M. Wermke1, J. Alt2, J. Kauh3, J. Back4, Y. Salhi5, V. Reddy6, M. Barve7, S. Ochsenreither8

Author affiliations

  • 1 University Hospital Carl-gustav-carus, University Hospital Carl-Gustav-Carus, 01307 - Dresden/DE
  • 2 University Medical Center, Johannes Gutenberg University Mainz, 55122 - Mainz/DE
  • 3 Clinical Sciences, Glenmark Pharmaceuticals, Inc, 07430 - Mahwah/US
  • 4 Drug Discovery, Glenmark Pharmaceuticals, SA, 2300 - La Chaux-de-Fonds/CH
  • 5 Biometrics, Glenmark Pharmaceuticals, Inc, 07430 - Mahwah/US
  • 6 Biologics Research, Glenmark Pharmaceuticals, Inc, 07430 - Mahwah/US
  • 7 Oncology, Mary Crowley Cancer Research, 75230 - Dallas/US
  • 8 Charité Comprehensive Cancer Center, Charité University of Medicine, 10117 - Berlin/DE

Abstract 1527


GBR 1302 is a HER2xCD3 bispecific antibody engineered to direct T-cells to HER2expressing tumor cells. This ongoing firstinhuman study (NCT02829372) in subjects with HER2positive cancers aims to evaluate the safety, tolerability, and preliminary efficacy of GBR 1302.


Adults with HER2-positive (immunohistochemistry 2+ or 3+) solid tumors with no available standard treatment receive GBR 1302 on Day 1 and Day 15 in 28-day treatment cycles at escalating dose levels, starting at 1 ng/kg. The primary endpoint includes determination of the maximum tolerable dose and safety profile of GBR 1302. Secondary and exploratory endpoints include pharmacodynamic (PD) testing for modulation of cellular and cytokine biomarkers.


To date, 19 evaluable subjects for dose limiting toxicity (DLT) have been treated up to a dose of 750 ng/kg; dose escalation is ongoing. Grade (G) 1 to 2 infusion related reaction (IRR)/cytokine release syndrome (CRS) is the most comment treatment emergent adverse event that has been observed in subjects treated at doses ≥100 ng/kg. The majority of subjects were managed with conservative treatment. 2 subjects experienced DLT events: one asymptomatic subject (100 ng/kg) was noted to have reduced left ventricular ejection fraction on routine echocardiogram at 4 weeks, which resolved spontaneously after treatment discontinuation; the second subject (500 ng/kg) experienced G4 IRR/CRS which required ICU care but resolved within 36 hours. Beginning at 30 ng/kg, CD3, CD4, and CD8 positive T-cell populations decreased within 6 hours of administration and recovered to levels at or above baseline by 48 hours. Dose-proportional, transient increases in cytokines (IL-2, IL-6, IL-10, IFN-γ, TNF-α), which peaked at 6 hours and began to normalize within 48 hours, were observed. No subjects have documented radiological response, but 2 subjects (HER2 3+ gastroesophageal adenocarcinoma and HER2 2+ breast adenocarcinoma) have prolonged disease stabilization lasting ≥4 months.


The combination of clinical findings and PD changes suggests T-cell activation with higher dosages of GBR 1302. Dose escalation is continuing and updated results will be presented.

Clinical trial identification


Legal entity responsible for the study

Glenmark Pharmaceuticals, SA.


Glenmark Pharmaceuticals, SA.

Editorial Acknowledgement

Editorial assistance provided by Ashley Skorusa, PhD of Prescott Medical Communications Group (Chicago, IL) and funded by Glenmark Pharmaceuticals S.A., Switzerland.


M. Wermke: Honoraria: BMS, Novartis, Roche, Bayer, Glenmark, AstraZeneca; Travel reimbursements: AstraZeneca, BMS, MSD, Novartis, Glenmark; Research funding: Novartis, Pfizer. J. Kauh, Y. Salhi, V. Reddy: Employee: Glenmark Pharmaceuticals, Inc. J. Back: Employee: Glenmark Pharmaceuticals, SA. S. Ochsenreither: Payment for scientific advice: Glenmark. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.